Arcutis Biotherapeutics, Inc. (ARQT) Q4 FY25 Earnings Call

Management raised 2026 guidance despite expected Q1 seasonality, supported by strong Zareve demand and expanding market access.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-01
Length73 minutes
EPS$0.13
Revenue$99.2M
Revenue consensus$111.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All ARQT earnings ยท Back to ARQT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.